Literature DB >> 11889274

The Tuberculosis Trials Consortium: a model for clinical trials collaborations.

.   

Abstract

Entities:  

Mesh:

Year:  2001        PMID: 11889274      PMCID: PMC1913687          DOI: 10.1093/phr/116.s1.41

Source DB:  PubMed          Journal:  Public Health Rep        ISSN: 0033-3549            Impact factor:   2.792


× No keyword cloud information.
  5 in total

1.  Using evaluation research methods to improve quality.

Authors:  J G Marshall
Journal:  Health Libr Rev       Date:  1995-09

Review 2.  Controlled chemoprophylaxis trials in tuberculosis. A general review.

Authors:  S H Ferebee
Journal:  Bibl Tuberc       Date:  1970

3.  Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium.

Authors:  A Vernon; W Burman; D Benator; A Khan; L Bozeman
Journal:  Lancet       Date:  1999-05-29       Impact factor: 79.321

4.  Noncompliance with directly observed therapy for tuberculosis. Epidemiology and effect on the outcome of treatment.

Authors:  W J Burman; D L Cohn; C A Rietmeijer; F N Judson; J A Sbarbaro; R R Reves
Journal:  Chest       Date:  1997-05       Impact factor: 9.410

5.  USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results.

Authors:  D L Combs; R J O'Brien; L J Geiter
Journal:  Ann Intern Med       Date:  1990-03-15       Impact factor: 25.391

  5 in total
  2 in total

1.  The challenge of multisite epidemiologic studies in diverse populations: design and implementation of a 22-site study of tuberculosis in foreign-born people.

Authors:  Amy L Davidow; Dolly Katz; Randall Reves; James Bethel; Lolem Ngong
Journal:  Public Health Rep       Date:  2009 May-Jun       Impact factor: 2.792

2.  Feasibility and reliability of health-related quality of life measurements among tuberculosis patients.

Authors:  M J Dion; P Tousignant; J Bourbeau; D Menzies; K Schwartzman
Journal:  Qual Life Res       Date:  2004-04       Impact factor: 4.147

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.